These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 6039128)

  • 1. Trial of appetite suppressant. Study of a short-acting and sustained release appetite suppressant on patients paired by initial weight.
    LeRiche WH; Csima A
    Appl Ther; 1967 Mar; 9(3):260-2. PubMed ID: 6039128
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of exogenous obesity: use of delayed action dimethylphenethylamine].
    Turatti S; de Netto GA
    Rev Bras Med; 1970 Jan; 27(1):57-63. PubMed ID: 5517811
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of exogenous obesity: use of delayed action dimethylphenethylamine].
    Turatti S; de Netto GA
    Rev Bras Med; 1970 Jan; 27(1):56-63. PubMed ID: 5517810
    [No Abstract]   [Full Text] [Related]  

  • 4. [Therapeutic activity and value of a delayed anorectic agent: amfepramone hydrochloride presented in microgranules].
    Linquette M; Fossati P
    Lille Med; 1971; 16(7):Suppl 3:902-8. PubMed ID: 5118952
    [No Abstract]   [Full Text] [Related]  

  • 5. [Study and evaluation of the results obtained in treatment of obese patients with new delayed action appetite depressants].
    Gómez Mont F; Vera Vallejo I
    Medicina (Mex); 1965 Jun; 45(966):273-6. PubMed ID: 5845683
    [No Abstract]   [Full Text] [Related]  

  • 6. The development of tolerance to drugs that suppress food intake.
    Fernstrom JD; Choi S
    Pharmacol Ther; 2008 Jan; 117(1):105-22. PubMed ID: 17950459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SUSTAINED RELEASE APPETITE SUPPRESSANT COMBINED WITH REDUCING DIET.
    LERICHE WH; CSIMA A
    Appl Ther; 1965 Mar; 7():226-8. PubMed ID: 14266244
    [No Abstract]   [Full Text] [Related]  

  • 8. [Experimental studies with the new appetite depressant N-(3-chlorpropyl)-1-methyl-2-phenylethylamine hydrochloride (Ro 4-5282)].
    Blum JE
    Arzneimittelforschung; 1969 May; 19(5):748-55. PubMed ID: 5819782
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
    Gaciong Z; Placha G
    J Hum Hypertens; 2005 Sep; 19(9):737-43. PubMed ID: 15905888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
    Flint A; Raben A; Astrup A; Holst JJ
    J Clin Invest; 1998 Feb; 101(3):515-20. PubMed ID: 9449682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The appetite-suppressant effect of nicotine is enhanced by caffeine.
    Jessen A; Buemann B; Toubro S; Skovgaard IM; Astrup A
    Diabetes Obes Metab; 2005 Jul; 7(4):327-33. PubMed ID: 15955118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacological, toxicological, deontologic, and medico-legal aspects of the use of appetite suppressant agents in "weight-loss cures"].
    Carolei L; Ermio G; Accorinti N; Meo G; Lamberti V; De Sarro G
    Minerva Med; 1997; 88(7-8):317-26. PubMed ID: 9304076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Insight: appetite suppressants.
    Bray GA
    Nat Clin Pract Gastroenterol Hepatol; 2005 Feb; 2(2):89-95. PubMed ID: 16265126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A long-acting appetite suppressant drug studied for 24 weeks in both continuous and sequential administration.
    Le Riche WH; Csima A
    Can Med Assoc J; 1967 Oct; 97(17):1016-20. PubMed ID: 6052900
    [No Abstract]   [Full Text] [Related]  

  • 15. An evaluation of the anorectic activity in man of a sustained release formulation of tiflorex.
    Silverstone T; Fincham J; Plumley J
    Br J Clin Pharmacol; 1979 Apr; 7(4):353-6. PubMed ID: 444355
    [No Abstract]   [Full Text] [Related]  

  • 16. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM; Caterson ID; Coutinho W; Finer N; Van Gaal L; Maggioni AP; Torp-Pedersen C; Bacher HP; Shepherd GM; James WP;
    Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A category of oral delayed and prolonged action drug: the pamoates].
    Saias E; Jondet A; Philippe J
    Ann Pharm Fr; 1969; 27(9):557-70. PubMed ID: 5395629
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials.
    Kim SH; Lee YM; Jee SH; Nam CM
    Obes Res; 2003 Sep; 11(9):1116-23. PubMed ID: 12972682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of resination on actions of anorexigenic agents.
    Zabik JE; Webb RW; Maickel RP
    Methods Find Exp Clin Pharmacol; 1981; 3(3):161-72. PubMed ID: 7253772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained-action phendimetrazine in obesity.
    Hadler AJ
    J Clin Pharmacol J New Drugs; 1968; 8(2):113-7. PubMed ID: 4871210
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.